Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 4/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.51 |
| ▸ | GLP1R | P43220 | 2/20 | 0.49 |
| ▸ | CCKAR | P32238 | 3/20 | 0.48 |
| ▸ | CCKBR | P32239 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299009 | 0.96 | OPRM1 (0.55) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL29804763 | 0.96 | OPRM1 (0.57) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL30477365 | 0.95 | OPRD1 (0.58) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL29378801 | 0.92 | BACE1 (0.54) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL31098023 | 0.90 | OPRD1 (0.60) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL31038686 | 0.90 | OPRD1 (0.58) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL29804647 | 0.89 | BACE1 (0.51) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL29674783 | 0.88 | OPRM1 (0.53) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL31257057 | 0.87 | OPRD1 (0.58) | OPRD1OPRM1OPRK1BACE1BACE2 | |
| SCHEMBL29960036 | 0.86 | OPRD1 (0.55) | OPRD1OPRM1OPRK1CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112074531-B | GIP derivative and use thereof | 诺和诺德股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| EP-3788063-B1 | GIP DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2023-08-09 | — | — | EP | claimed |
| CN-112074531-B | GIP derivative and use thereof | 诺和诺德股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240190938-A1 | GIP DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2024-06-13 | — | — | US | disclosed |
| EP-3788063-B1 | GIP DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2023-08-09 | — | — | EP | disclosed |
| US-11633459-B2 | GIP derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633459-B2 | GIP derivatives and uses thereof | GIPR, GLP1R, GPR119 | OPRD1 1176/4885OPRM1 861/4885OPRK1 698/4885 |
| US-20240190938-A1 | GIP DERIVATIVES AND USES THEREOF | GIPR, GLP1R, GPR119 | OPRD1 1176/4885OPRM1 861/4885OPRK1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.